EcoDrugPlus

Protein-Serine O-Palmitoleoyltransferase Porcupine-Like

Ensembl ID : ENSPNAG00000011886
Gene Symbol: LOC108437582
3 Cross references
197 Possible Orthologues:

Protein-Serine O-Palmitoleoyltransferase Porcupine-Like

Ensembl ID : ENSPNAG00000022862
Gene Symbol: LOC108441655
3 Cross references
192 Possible Orthologues:

Protein-Tyrosine Kinase 2-Beta-Like

Ensembl ID : ENSPNAG00000005382
Gene Symbol: LOC108434997
3 Cross references
195 Possible Orthologues:

Protein-Tyrosine Kinase 6-Like

Ensembl ID : ENSPNAG00000003404
Gene Symbol: LOC108435232
3 Cross references
159 Possible Orthologues:

Protein-Tyrosine Kinase 6-Like

Ensembl ID : ENSPNAG00000008785
Gene Symbol: LOC108412503
2 Cross references
107 Possible Orthologues:

Proteinase-Activated Receptor 1-Like

Ensembl ID : ENSPNAG00000010761
Gene Symbol: LOC108415651
3 Cross references
263 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Src

Ensembl ID : ENSPNAG00000021238
Gene Symbol: LOC108425539
3 Cross references
197 Possible Orthologues:

Purinergic Receptor P2x 3

Ensembl ID : ENSPNAG00000014553
Gene Symbol: P2RX3
3 Cross references
197 Possible Orthologues:

Purinergic Receptor P2x 7

Ensembl ID : ENSPNAG00000010872
Gene Symbol: P2RX7
3 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSPNAG00000017739
Gene Symbol: P2RY1
3 Cross references
190 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSPNAG00000018838
Gene Symbol: P2RY2
3 Cross references
197 Possible Orthologues:

Putative Transcription Factor P65 Homolog

Ensembl ID : ENSPNAG00000005984
Gene Symbol: LOC108427452
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).